Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week Phase 3 studies in patients with moderate to severe plaque psoriasis

被引：0

作者：

Kaur, M. ^{[1
]}

Merola, J. ^{[2
]}

Tatulych, S. ^{[3
]}

Mamolo, C. ^{[3
]}

Lan, S. ^{[3
]}

机构：

[1] Pfizer, Collegeville, PA USA

[2] Harvard Med Sch, Brigham & Womens Hosp, Dermatol, Boston, MA USA

[3] Pfizer, Groton, CT USA

来源：

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY | 2016年 / 30卷

关键词：

psoriasis; nails; tofacitinib;

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

P157

引用

页码：81 / 81

页数：1

共 50 条

[1] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
Merola, Joseph
Tatulych, Svitlana
Mamolo, Carla
Lan, Shuping
Mallbris, Lotus
Kaur, Mandeep
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB248 - AB248
[2] Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week phase 3 studies in patients with moderate to severe plaque psoriasis
Merola, Joseph
Tatulych, Svitlana
Kaur, Mandeep
Lan, Shuping
Mallbris, Lotus
Mamolo, Carla
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S9 - S9
[3] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis
Merola, Joseph F.
Elewski, Boni
Tatulych, Svitlana
Lan, Shuping
Tallman, Anna
Kaur, Mandeep
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (01) : 79 - +
[4] Two phase 3 studies of oral tofacitinib in patients with moderate to severe plaque psoriasis: 16-week efficacy and safety results
Papp, Kim A.
Menter, Martin A.
Abe, Masatoshi
Elewski, Boni E.
Feldman, Steven R.
Gottlieb, Alice G.
Thaci, Diamant
Luger, Thomas
Tatulych, Svitlana
Gupta, Pankaj
Proulx, James
Lan, Shu-Ping
Wolk, Robert
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB66 - AB66
[5] Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
Yoshinori Umezawa
Akihiko Asahina
Shinichi Imafuku
Yayoi Tada
Shigetoshi Sano
Akimichi Morita
Shinya Sakurai
Naoki Hoshii
Nicola Tilt
Hidemi Nakagawa
Dermatology and Therapy, 2021, 11 : 943 - 960
[6] Efficacy and Safety of Certolizumab Pegol in Japanese Patients with Moderate to Severe Plaque Psoriasis: 52-Week Results
Umezawa, Yoshinori
Asahina, Akihiko
Imafuku, Shinichi
Tada, Yayoi
Sano, Shigetoshi
Morita, Akimichi
Sakurai, Shinya
Hoshii, Naoki
Tilt, Nicola
Nakagawa, Hidemi
DERMATOLOGY AND THERAPY, 2021, 11 (03) : 943 - 960
[7] Efficacy and safety of infliximab biosimilar in the treatment of moderate-to-severe plaque psoriasis: A 52-week clinical study
Panagakis, Pantelis
Rompoti, Natalia
Stravodimou, Aristea
Papoutsaki, Marina
Rigopoulos, Dimitrios
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB198 - AB198
[8] Evaluation of efficacy and safety of ABP 501 in a phase 3 study in subjects with moderate to severe plaque psoriasis: 52-week results
Strober, Bruce
Foley, Peter
Philipp, Sandra
Zhang, Nan
Kaur, Primal
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB249 - AB249
[9] Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
Wasel, Norman
Thaci, Diamant
French, Lars E.
Conrad, Curdin
Dutronc, Yves
Gallo, Gaia
Berggren, Lovisa
Lacour, Jean-Philippe
DERMATOLOGY AND THERAPY, 2020, 10 (04) : 663 - 670
[10] Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
Norman Wasel
Diamant Thaçi
Lars E. French
Curdin Conrad
Yves Dutronc
Gaia Gallo
Lovisa Berggren
Jean-Philippe Lacour
Dermatology and Therapy, 2020, 10 : 663 - 670

← 1 2 3 4 5 →